VistaGen Therapeutics (NASDAQ:VTGN) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened

VistaGen Therapeutics, Inc. (NASDAQ:VTGN)’s share price crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.55 and traded as low as $0.61. VistaGen Therapeutics shares last traded at $0.6249, with a volume of 655,298 shares changing hands.

Analyst Ratings Changes

Several research firms recently weighed in on VTGN. Weiss Ratings reiterated a “sell (d-)” rating on shares of VistaGen Therapeutics in a report on Wednesday, January 21st. Wall Street Zen downgraded shares of VistaGen Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Four research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, VistaGen Therapeutics has a consensus rating of “Reduce” and an average target price of $0.95.

VistaGen Therapeutics Price Performance

The company’s 50 day simple moving average is $0.60 and its 200 day simple moving average is $1.55. The firm has a market cap of $24.76 million, a price-to-earnings ratio of -0.33 and a beta of 0.31.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings results on Thursday, February 12th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.06. The business had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.14 million. As a group, analysts forecast that VistaGen Therapeutics, Inc. will post -1.88 earnings per share for the current year.

Institutional Investors Weigh In On VistaGen Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Luminus Management LLC purchased a new stake in shares of VistaGen Therapeutics in the fourth quarter valued at about $232,000. Two Sigma Investments LP increased its stake in shares of VistaGen Therapeutics by 223.5% during the third quarter. Two Sigma Investments LP now owns 289,409 shares of the company’s stock worth $1,027,000 after acquiring an additional 199,958 shares during the period. Millennium Management LLC increased its stake in shares of VistaGen Therapeutics by 853.0% during the fourth quarter. Millennium Management LLC now owns 197,045 shares of the company’s stock worth $130,000 after acquiring an additional 176,369 shares during the period. Renaissance Technologies LLC increased its stake in shares of VistaGen Therapeutics by 81.2% during the first quarter. Renaissance Technologies LLC now owns 291,300 shares of the company’s stock worth $166,000 after acquiring an additional 130,509 shares during the period. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of VistaGen Therapeutics during the fourth quarter worth about $68,000. 78.39% of the stock is owned by hedge funds and other institutional investors.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.